The effect of dialysis membrane type on plasma concentrations of pentosidine, a marker of carbonyl stress, in hemodialyzed patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 10, 2009, Pages 614-620

  Słowik Zyłka, Dorota ^a   Safranow, Krzysztof ^a   Dziedziejko, Violetta ^a   Ciechanowski, Kazimierz ^a   Dziewanowski, Krzysztof ^b   Chlubek, Dariusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Marie Curie Hospital   (Poland)

Author keywords

Carbonyl stress; Hemodialysis; Pentosidine; Polysulfone membranes

Indexed keywords

PENTOSIDINE; PLASMA PROTEIN; POLYSULFONE; TRICHLOROACETIC ACID;

ADULT; ARTICLE; CARBONYL STRESS; DIALYSIS MEMBRANE; FEMALE; FLUORESCENCE ANALYSIS; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS;

EID: 72249120629     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.785     Document Type: Article

References (35)

1. Sell D, Monnier V. Structure elucidation of a fluorescent crosslink from human senescent extracellular matrix: implication of pentoses in the aging process. J Biol Chem. 1989; 264: 21597-21602. (Pubitemid 20028722)
2. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991; 325: 836-842.
3. Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes. 1992; 41: 1286-1292.
4. Miyata T, Ueda Y, Shinzato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the patophysiology of pentosidine. J Am Soc Nephrol. 1996; 7: 1198-1206. (Pubitemid 27468273)
5. Takahashi M, Kushida K, Kawana K, et al. Quantification of the cross-link pentosidine from normal and uremic subjects. Clin Chem. 1993; 39: 2162-2165. (Pubitemid 23306169)
6. Bowlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984; 101: 527-537. (Pubitemid 14018054)
7. Chappey O, Dosquet C, Wautier MP, et al. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997; 27: 97-108. (Pubitemid 27101380)
8. Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrol Dial Transplant 1996; 11: 17-19. (Pubitemid 27062905)
9. Khoury JE, Thomas CA, Loike JD, et al. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem. 1994; 269: 10197-10200.
10. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994; 269: 9889-9897.
11. Mahiout A, Ehlerding G, Brunkhorst R. Advanced glycation end products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrol Dial Transplant. 1996; 11: 2-6. (Pubitemid 27062902)
12. Makita Z, Yanagisawa K, Kuwajima S, et al. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant. 1996; 11 (Suppl 5): 31-33. (Pubitemid 27062908)
13. 2- microglobulin containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA. 1996; 93: 2353-2358. (Pubitemid 26104354)
14. Głowińska I, Grochowski J, Małyszko J. Cardiovascular complications in patients with diabetic nephropathy receiving pharmacological versus renal replacement therapy. Pol Arch Med Wewn. 2008; 118: 404-412.
15. Miyata T, Saito A, Kurokawa K, et al. Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uremic toxicity. Nephrol Dial Transplant. 2001; 16: 8-11. (Pubitemid 32591152)
16. Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycosylation end product: carbonyl stress in uremia. J Am Soc Nephrol. 1998; 9: 2349-2356. (Pubitemid 28543814)
17. Słowik-Żyłka D. Reduction of carbonyl stress with renal replacement therapy in chronic renal failure. Ann Acad Med Stetin. 2004; 50: 5-15.
18. Słowik-Żyłka D, Safranow K, Dziedziejko V, et al. A sensitive and specific HPLC method for the determination of total pentosidine concentration in plasma. J Biochem Biophys Methods. 2004; 61: 313-329. (Pubitemid 39574945)
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254.
20. Słowik-Żyłka D, Safranow K, Dziedziejko V, et al. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients. J Nephrol. 2006; 19: 65-69.
21. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in haemodialysis. Kidney Int 1999; 56: 2005-2015.
22. Stein G, Franke S, Sperschneider H, et al. Decrease in serum pentosidine levels of ESRD patients during polysulfone hemodialysis. Nephrol Dial Transplant. 1999; 14: 1606-1608. (Pubitemid 29241772)
23. Miyata T, Ueda Y, Yoshida A, et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int. 1997; 51: 880-887. (Pubitemid 27157977)
24. Jadoul M, Ueda Y, Yasuda Y, et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of carbonyl stress. Kidney Int. 1999; 55: 2487-2492. (Pubitemid 29256504)
25. Stein G, Franke S, Mahiout A, et al. Influence of dialysis modalities on serum AGEs levels in end-stage renal disease patients. Nephrol Dial Transplant. 2001; 16: 999-1008. (Pubitemid 32440373)
26. Klemm A, Franke C, Busch M, et al. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites. Clin Nephrol. 2004; 61: 191-197. (Pubitemid 38396910)
27. Odetti P, Cosso L, Pronzato MA, et al. Plasma advanced glycosylation end-products in maintenance hemodialysis patients. Nephrol Dial Transplant. 1995; 10: 2110-2113.
28. Takahashi M, Kushida K, Ishihara C, et al. Plasma pentosidine levels in uremic patients before and after hemodialysis. Scand J Urol Nephrol. 1995; 29: 131-134.
29. Henle T, Deppisch R, Beck W, et al. Advanced glycated end-products (AGEs) during hemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGEs compounds. Nephrol Dial Transplant. 1999; 14: 1968-1975. (Pubitemid 29358896)
30. Miyata T, van Ypersele de Strihou C, Kurokawa K, et al. Alterations in nonenzymatic biochemistry in uremia: origin and significance of carbonyl stress in long-term uremic complications. Kidney Int. 1999; 55: 389-399. (Pubitemid 29082866)
31. Becker BN, Himmelfarb J, Henrich WL, et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol. 1997; 8: 475-486. (Pubitemid 127454184)
32. Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in haemodialysis. QJM. 1994; 87: 679-683.
33. Pawlak K, Pawlak D, Myśliwiec M. [Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure]. Pol Arch Med Wewn. 2005; 113: 21-26. Polish.
34. Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997; 51: 1170-1181. (Pubitemid 27186543)
35. Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998; 161: 2524-2532. (Pubitemid 28397070)